Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes. TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery-operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (<10 Hz) with an intensity that produces motor contraction. While the use of TENS has proved effective in clinical studies, there is controversy over which conditions the device should be used to treat.
Market Analysis: Global transcutaneous electrical nerve stimulators market is expected to witness a healthy CAGR in the forecast period of 2019-2026. The report contains data from the historic year of 2017, and the base year of 2018. This healthy rise of market value can be attributed to the rising applications of the products due to the continuous research & developments efforts in the market for the advancement of the product.
Market Definition: Transcutaneous electrical nerve stimulation (TENS) is a procedure that involves electrical stimulation with the primary aim of providing a symptomatic pain relief by exciting sensory nerves, thereby, stimulating either the opioid system or the pain gate mechanism. In simpler words, it involves the usage e of low voltage electric currents to treat pain.
Key Market Competitors:
- Boston Scientific Corporation
- Cyberonics, Inc.
- DJO LLC.
- Nevro Corp.
- NeuroMetrix, Inc.
- Uroplasty Inc.
- Cogentix Medical
- Zynex MedicalCochlear Ltd
- Aleva Neurotherapeutics SA
- NeuroPace Inc. and others
- Adoption of transcutaneous electrical nerve stimulators by the emerging countries
- Growing market of transcutaneous electrical nerve stimulators
Avail 10% Discount On This Report Click HERE | Reasons to Purchase this Report:
Current and future of global transcutaneous electrical nerve stimulators market outlook in the developed and emerging markets, The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period, Regions/Countries that are expected to witness the fastest growth rates during the forecast period, The latest developments, market shares, and strategies that are employed by the major market players
- Lack of skilled or trained physicians
- High cost of nerve stimulation therapy
Segmentation: Global Transcutaneous Electrical Nerve Stimulators Market
- By Surgery Procedures
- Direct Nerve Repair
- Nerve Grafting
- Stem cell therapy
- By Product
- By End User
- By Geography
- North America
- South America
- Rest of South America
- United Kingdom
- Rest of Europe
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- South Africa
- Saudi Arabia
- United Arab Emirates
- Rest of Middle East & Africa
- North America
Competitive Analysis: Global transcutaneous electrical nerve stimulators market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of transcutaneous electrical nerve stimulators market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.
Key Developments in the Market:
- In June 2018, Bioness,Inc., announced the first successful implants of StimRouter Neuromodulation System for the treatment of chronic pain at Women’s College Hospital in Toronto, Canada.
- In April 2017, electroCore, announced that the S. Food and Drug Administration (FDA) released the use of gammaCore (non-invasive vagus nerve stimulator) for the acute treatment of pain associated with episodic cluster headache in adult patients.